Tag: NASDAQ:RPRX

Finance

Trader’s Recap: Blucora, Inc. (NASDAQ:BCOR), Weatherford International plc (NYSE:WFT), NVR, Inc. (NYSE:NVR), The Blackstone Group L.P. (NYSE:BX), Repros Therapeutics Inc. (NASDAQ:RPRX)

On Nov 25, TaxACT®, a business of Blucora, Inc. (NASDAQ: BCOR), announced to empowers Americans to confidently navigate Affordable Care Act open enrollment and taxes. Blucora, Inc. (NASDAQ:BCOR) belongs to Technology sector. Its net profit margin is 4.90% and weekly performance is -0.84%. On last trading day company shares ended up $14.12. Blucora, Inc. (NASDAQ:BCOR) distance from 50-day simple moving average (SMA50) is -7.66%. In … Continue reading Trader’s Recap: Blucora, Inc. (NASDAQ:BCOR), Weatherford International plc (NYSE:WFT), NVR, Inc. (NYSE:NVR), The Blackstone Group L.P. (NYSE:BX), Repros Therapeutics Inc. (NASDAQ:RPRX)

Kevin Long
Finance

Morning Alert: Repros Therapeutics Inc. (NASDAQ:RPRX), Hewlett-Packard Company (NYSE:HPQ), Flowers Foods, Inc. (NYSE:FLO), American River Bankshares (NASDAQ:AMRB), Delta Air Lines, Inc. (NYSE:DAL)

Repros Therapeutics Inc. (NASDAQ:RPRX) on Oct. 21 reported results from a large, controlled, long-term safety study comparing Androxal(R) to a placebo. In this study of Androxal(R), ZA-303, no new safety signals were identified, including no evidence of negative effects on bone mineral density. Over 79% of the Androxal(R)-treated subjects had morning testosterone levels above 300 ng/dL after being treated for 12 months. Repros Therapeutics Inc. … Continue reading Morning Alert: Repros Therapeutics Inc. (NASDAQ:RPRX), Hewlett-Packard Company (NYSE:HPQ), Flowers Foods, Inc. (NYSE:FLO), American River Bankshares (NASDAQ:AMRB), Delta Air Lines, Inc. (NYSE:DAL)

Mark Doerr
Finance

Market Movers : Hertz Global (NYSE:HTZ), IAMGOLD (NYSE:IAG), Repros Therapeutics Inc. (NASDAQ:RPRX), Rocket Fuel Inc. (NASDAQ:FUEL), Genomic Health Inc. (NASDAQ:GHDX),

Hertz Global Holdings (NYSE:HTZ) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research note issued on Tuesday. They currently have a $26.10 target price on the stock. Zacks‘s target price suggests a potential downside of 5.43% from the stock’s previous close. Hertz Global Holdings, Inc. (NYSE:HTZ) belongs to Services sector. Its net profit margin is 6.50% and weekly performance … Continue reading Market Movers : Hertz Global (NYSE:HTZ), IAMGOLD (NYSE:IAG), Repros Therapeutics Inc. (NASDAQ:RPRX), Rocket Fuel Inc. (NASDAQ:FUEL), Genomic Health Inc. (NASDAQ:GHDX),

Kevin Long
Finance

Top News : Repros Therapeutics (NASDAQ:RPRX), J. C. Penney Company (NYSE:JCP), Sutron (NASDAQ:STRN), Microsoft Corporation (NASDAQ:MSFT), Journal Communications Inc. (NYSE:JRN)

Repros Therapeutics Inc. (NASDAQ:RPRX) is up almost 20% during trading, on news of successful trial results for its low testosterone treating drug. The trial of the drug was being conducted against a leading treatment of low testosterone and a placebo with two primary end-points. Repros’s drug Androxal showed better results in both measures of the trial and also had statistically significant results for the secondary … Continue reading Top News : Repros Therapeutics (NASDAQ:RPRX), J. C. Penney Company (NYSE:JCP), Sutron (NASDAQ:STRN), Microsoft Corporation (NASDAQ:MSFT), Journal Communications Inc. (NYSE:JRN)

Ryan Holtz
Finance

Stocks in Focus : Sarepta Therapeutics (NASDAQ:SRPT), Google Inc (NASDAQ:GOOGL), B&G Foods Inc. (NYSE:BGS), Repros Therapeutics Inc. (NASDAQ:RPRX), Tejon Ranch (NYSE:TRC)

Chris Garabedian, President and CEO Sarepta Therapeutics, Inc. (NASDAQ:SRPT), announced that the Phase IIb clinical study on its first product, eteplirsen, will have its results submitted to the FDA by the end of the year, with a launch slated for mid next-year if approved. He was speaking at the Canaccord Genuity 34th Annual Growth Conference at the Intercontinental Hotel in Boston, Massachusetts. Sarepta Therapeutics, Inc. … Continue reading Stocks in Focus : Sarepta Therapeutics (NASDAQ:SRPT), Google Inc (NASDAQ:GOOGL), B&G Foods Inc. (NYSE:BGS), Repros Therapeutics Inc. (NASDAQ:RPRX), Tejon Ranch (NYSE:TRC)

Colin Pettis